P-nitrobenzyl 2-diazoacetoacetate

- Jun 08, 2018 -


In recent years, the global developed countries are generally faced with the problem of increasing health care payment pressure, and the demand for generic drugs with high quality and low price has increased obviously. The arrival of the global patent cliffs of innovative drugs also provides an opportunity for a large number of generic drugs to go on the market.


According to projections, generic drugs will continue to be a major contributor to the growth of the pharmaceutical market in the coming years. The global drug market is expected to grow to $1.2249 trillion in 2019 from about $976.1 billion in 2014, with generic drugs growing by about $150 billion, accounting for 60 percent of the growth in the drug market. At the same time, during the period 2009-2013, the growth rate of the global generic drug market was about 4- 8 per cent higher than the overall growth rate of the global drug market, which shows that generic drugs are an important factor driving the growth of the global drug market. The development of generic drug market is still facing a good market opportunity


The world's largest generics manufacturers are concentrated in the United States and Europe. According to sales, the top 10 generics companies include Teva , Sandoz /Novartis Myron and Actavis among others. The above enterprises occupy 20% of the market share of generic drugs. In order to control the production cost, the generics giants have transferred their production bases to China and India, which provides a good opportunity for the development of generic drugs in Asia.










Related News

Related Products

  • Herbicide
  • 2-Methylsulfony-45-Dimethoxypyridine
  • Diazonio-(4-methylphenyl)sulfonylazanide
  • C18H29N3O2S
  • P-Nitrobenzyl -diazoacetoacetate
  • C7H6FNO3